RNC Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

RNC Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-7,980	Closed	-$289K	–	155
2016 Q4	$289K	Sell	7,980 -413,805	-98%	-$16.5M	0.02%	122
2016 Q3	$19.4M	Buy	421,785 +28,815	+7%	+$1.5M	1.72%	30
2016 Q2	$19.7M	Buy	392,970 +311,856	+384%	+$16.6M	1.84%	27
2016 Q1	$4.34M	Sell	81,114 -1,081	-1%	-$63.4K	0.43%	50
2015 Q4	$5.39M	Sell	82,195 -575	-0.7%	-$35.5K	0.54%	49
2015 Q3	$4.67M	Buy	82,770 +655	+0.8%	+$42.5K	0.45%	48
2015 Q2	$4.85M	Buy	+82,115	New	+$5.07M	0.41%	50
2014 Q2	–	Sell	-10,000	Closed	-$528K	–	131
2014 Q1	$528K	Buy	+10,000	New	+$462K	0.05%	84

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RNC Capital Management's TEVA Position: Q1 2017 in Review

RNC Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 7,980 shares — an estimated $289K sold.

RNC Capital Management first reported a position in TEVA in Q1 2014 and held it in 8 quarters. The position peaked at $19.7M in Q2 2016. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

RNC Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
RNC Capital Management sold 7,980 Teva Pharmaceuticals shares in Q1 2017, an estimated $289K.
RNC Capital Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 8 quarters.
RNC Capital Management's Teva Pharmaceuticals position peaked at $19.7M in Q2 2016.
686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on RNC Capital Management's 13F filing for Q1 2017, filed 4 May 2017.